WallStSmart
ALVO

Alvotech

NASDAQ: ALVO · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$3.59
-5.35% today

Updated 2026-06-05

Market cap
$1.05B
P/E ratio
33.60
P/S ratio
1.87x
EPS (TTM)
$0.10
Dividend yield
52W range
$3 – $12
Volume
0.5M

WallStSmart proprietary scores

21
out of 100
Grade: F
Strong Sell
Investment rating
4.7
Growth
C
5.5
Quality
C+
4.5
Profitability
C
6.3
Valuation
B
2/9
Piotroski F-Score
Weak
-1.0
Altman Z-Score
Distress
Industry rank
View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target
$13.83
+285.24%
12-Month target
$2.40
-33.15%
Intrinsic (DCF)
$24.48
Margin of safety
+80.19%
1 Strong Buy3 Buy1 Hold0 Sell1 Strong Sell

Price chart

Stock snapshot

Strengths
+ 80.19% below intrinsic value
+ Debt/equity -5.16x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Altman Z -1.02 — distress zone
- Thin margins at -14.40%
- Negative free cash flow $-67.57M
- Revenue declining -20.20% QoQ

Key financials

Revenue Net Income Free Cash Flow
Metric2022202320242025TTM
Revenue$83.03M$91.43M$489.68M$586.32M$562.04M
Net income$-513.58M$-551.73M$-231.86M$27.92M$1.03M
EPS$0.10
Free cash flow$-361.39M$-358.66M$-293.84M$-114.67M$-67.57M
Profit margin-618.55%-603.42%-47.35%4.76%-14.40%

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
ALVO$1.05B214.74.56.35.5+80.19%Avoid
LLY$948.95B7810.010.05.06.0Strong Buy
JNJ$536.54B594.79.03.36.0-71.41%Buy
ABBV$380.57B634.08.04.05.0-55.64%Buy
UNH$343.21B545.35.54.75.5-26.61%Buy
MRK$285.64B503.38.02.75.0-49.34%Hold

Smart narrative

Alvotech trades at $3.59. representing a P/E of 33.60x trailing earnings. Our Smart Value Score of 21/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -1.02, it sits in the distress. TTM revenue stands at $562.04M. with profit margins at -14.40%. Our DCF model estimates intrinsic value at $24.48.

Frequently asked questions

What is Alvotech's stock price?

Alvotech (ALVO) trades at $3.59, on a P/E of 33.6x and a P/S of 1.9x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.

Is Alvotech overvalued?

Alvotech carries a Smart Value Score of 21/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $24.48 versus the $3.59 price, a 80.2% margin of safety on a cash flow basis.

What is the price target of Alvotech (ALVO)?

The 12-month analyst consensus target is $13.83, about 285.2% above the current $3.59. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

What is the future stock price of ALVO by 2030?

Our research-backed model puts the 2030 base case at $4.64, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.

What is the intrinsic value of Alvotech (ALVO)?

Our DCF model estimates intrinsic value at $24.48, a +80.2% margin of safety versus today's $3.59. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.

What is Alvotech's revenue?

Alvotech's trailing twelve-month revenue is $562.04M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.

Altman Z-Score?

Alvotech's Altman Z-Score is -1.02, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNASDAQ
CurrencyUSD

Quick metrics

P/S ratio1.87x
ROE
Beta0.21
50D MA$3.45
200D MA$5.47
Shares out0.31B
Float0.11B
Short ratio
Avg volume0.5M

Performance

1 week-6.86%
1 month-9.94%
3 months-37.31%
YTD-36.45%
1 year
3 years
5 years